Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$115.95 USD
-2.68 (-2.26%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $115.96 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AXSM 115.95 -2.68(-2.26%)
Will AXSM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AXSM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXSM
Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
AXSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings
Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates
Other News for AXSM
Technical picture remains unchanged for AXSM after it rises 1.72% on September 18
Axsome Therapeutics: Strong Growth Trajectory and Financial Outlook Justify Buy Rating
Axsome Therapeutics, Inc. (AXSM) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript
AXSM's price rises by 2.21% on September 18, though its technical setup remains stable.
Fairmount Funds Management LLC Increases Stake in Dianthus Therapeutics Inc